{"links":{"html":"https://www.erudio.com/reports/skyscraper-03-nct04513925","json":"https://www.erudio.com/reports/skyscraper-03-nct04513925.json","markdown":"https://www.erudio.com/reports/skyscraper-03-nct04513925.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"skyscraper-03-04513925"}},"request":"https://www.erudio.com/contact?report=skyscraper-03-04513925"},"offer":{"cited_commentary_sources":39,"verified_hcp_statements":122,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":35,"optional":true,"price_per_verified_person_usd":15,"price_usd":525,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"skyscraper-03-nct04513925"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=skyscraper-03-04513925","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/skyscraper-03-nct04513925","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T11:25:53.638069Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":11,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":11,"title":"Primary endpoint: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)"},{"claim_count":7,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":7,"title":"Primary endpoint: PFS, as Assessed by an IRF in FAS"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":20,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":14,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":6,"title":"Biomarker strategy, sample access and continued development"},{"claim_count":13,"coverage":"discussed","id":"A2","source_count":9,"title":"Pre-result expectations and limits of anti-TIGIT extrapolation"},{"claim_count":22,"coverage":"discussed","id":"A3","source_count":8,"title":"Consolidation alternatives and treatment sequencing"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":1,"title":"Radiation planning, local control and consolidation eligibility"},{"claim_count":20,"coverage":"discussed","id":"A5","source_count":8,"title":"Scientific value of negative trials and expectations for progress"}],"counts":{"cited_sources":43,"claims_by_expression_type":{"comparison":4,"experience":1,"interpretation":30,"opinion":25,"primary_context":10,"question":9,"restatement":29,"uncertainty":9,"unspecified":5},"claims_by_kind":{"protocol_statement":6,"publication_statement":3,"source_observation":113},"clinician_statements":69,"evidence_units":105,"findings":8,"organisational_accounts":5,"people_cited":40,"people_identity_verified":35,"people_total":40,"screened_sources":79,"verified_claims":122},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":5,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":9,"passages":13,"sources":12,"sources_by_kind":{"commentary":8,"media":2,"publication":1,"registry":1}},"title":"The principal clinical reading is an unchanged durvalumab benchmark, not proof of equivalence"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":2,"views":2},"has_counterview":true,"limitations":2,"links":{"context":1,"support":7},"ma_question":true,"named_voices":6,"passages":7,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Safety reassurance coexists with concern about added treatment burden"},{"id":"F3","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":7,"passages":8,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Biomarker refinement is a contested development strategy, not an established solution"},{"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":5,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":6,"sources_by_kind":{"commentary":5,"publication":1}},"title":"Selection effects and inconsistent numerical reporting qualify interpretation"},{"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":1,"views":6},"has_counterview":true,"limitations":2,"links":{"context":3,"support":11},"ma_question":true,"named_voices":7,"passages":9,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Earlier biological hope and skepticism should not be flattened into retrospective certainty"},{"id":"F6","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":0,"questions":6,"restated":5,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":17},"ma_question":true,"named_voices":6,"passages":12,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Competing consolidation and sequencing strategies remain evidence-dependent alternatives"},{"id":"F7","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":6},"has_counterview":true,"limitations":3,"links":{"context":1,"support":10},"ma_question":true,"named_voices":5,"passages":9,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Radiation planning is proposed as a route to both local control and consolidation eligibility"},{"id":"F8","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":13},"has_counterview":true,"limitations":3,"links":{"context":3,"support":19},"ma_question":true,"named_voices":8,"passages":19,"sources":8,"sources_by_kind":{"commentary":6,"media":2}},"title":"Negative evidence is valued, but clinicians disagree about how much it sets the field back"}],"medical_affairs_question":"Which patients, if any, could justify further intensification, and what evidence would distinguish a genuinely different strategy from repetition of an unsuccessful one?","sections":{"analysis":[{"id":"section-1","level":3,"title":"1. An unchanged benchmark, not an equivalence finding"},{"id":"section-2","level":3,"title":"2. Familiar safety does not mean an absence of added burden"},{"id":"section-3","level":3,"title":"3. Biomarkers divide a plausible next step from a potentially repetitive development strategy"},{"id":"section-4","level":3,"title":"4. Population selection and reporting details matter to the clinical inference"},{"id":"section-5","level":3,"title":"5. Preserve the timing and limits of mechanistic expectations"},{"id":"section-6","level":3,"title":"6. Alternative combinations and sequences require their own comparisons"},{"id":"section-7","level":3,"title":"7. Local treatment and immune preservation offer a different improvement hypothesis"},{"id":"section-8","level":3,"title":"8. A useful negative trial can still be experienced as a major setback"},{"id":"section-9","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T2","label":"Primary endpoint: PFS, as Assessed by an IRF in FAS"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":1},{"id":"F8","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":7}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T11:25:53.638069Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T11:39:50Z","record_hash":"9af50cb9fb603b8a831ddad0891324c7eb720f5587bfc3df8bdbd5bdeec360d2","release_hash":"3c813f180d343cb43d898d33397c249f0128664c85c45f29da75861aa7b96b2f","report_id":"erudio-nct04513925","run_id":"307a7a8e-a2d1-454a-bf88-bf61c38ff4c4","schema_version":"5.0","slug":"skyscraper-03-04513925","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"SKYSCRAPER-03 asks whether atezolizumab plus tiragolumab can delay progression more than durvalumab in unresectable stage III NSCLC following concurrent chemoradiation without progression. Commentary spans X, Bluesky and LinkedIn posts, podcasts and YouTube, including physicians with confirmed oncology roles. The discussion turns on what an unchanged durvalumab benchmark means and how safety reassurance should be weighed against treatment burden. Whether biomarker refinement can guide treatment intensification remains contested.","meta_description":"79 sources screened · 122 verified statements (69 from clinicians verified by NPI or staff page) from 43 sources · 8 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-c3403ec7de42901dae2a","claim-1e54f9df807c061ebc43"],"id":"F3","paraphrase":"An X post addressed how to identify patients who might benefit from intensification after chemoradiation in the SKYSCRAPER-03 setting.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-08-23","title":"Biomarker refinement is a contested development strategy, not an established solution"},{"cited_claim_ids":["claim-542d962cd280280b4c9e"],"id":"F4","paraphrase":"An X post addressed methodological questions about statistical testing and the histologic composition of the SKYSCRAPER-03 population.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2025-10-18","title":"Selection effects and inconsistent numerical reporting qualify interpretation"}]},"publication":{"approved_at":"2026-10-31T11:39:50Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":79},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on radiotherapy’s immune effects and alternative ways to combine immunotherapy with radiotherapy.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","67 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion; frequencies and consensus cannot be estimated.","Some additional passages were not fully assessed, and discussion using unnamed references or different spellings may be missing.","Organizational accounts, relayed publications or presentations, repeated posts and multiple versions of one episode do not establish additional independent HCP views.","A remark about continued tiragolumab development cannot be assigned reliably to a speaker across the podcast and video versions of the same episode; it is not included as an attributed position or counted as separate views.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","PD-L1-positive PFS hazard ratios and p-values differ between some social accounts and the publication; the sources do not explain why.","Comments about PACIFIC-2, PACIFIC 6, DATE, COAST, CODE, I-SABR and other approaches retain their own population, timing and evidentiary limits and are not SKYSCRAPER-03 results.","No exact product-label source is available for atezolizumab or tiragolumab; no approval or label conclusion is drawn."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":3,"other":0,"podcast":3,"publication":1,"registry":3,"regulatory":0,"x_thread":29,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":39,"context":1,"methods":3},"count":43,"evidence_window":{"end":"2026-08-23","start":"2022-01-10"},"retrieval_snapshot":"2026-10-31T10:05:21.431483Z","timeline":[{"count":1,"week":"2022-W02"},{"count":1,"week":"2022-W03"},{"count":1,"week":"2022-W08"},{"count":1,"week":"2022-W15"},{"count":1,"week":"2022-W17"},{"count":1,"week":"2022-W18"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2024-W03"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W39"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W41"},{"count":11,"week":"2025-W42"},{"count":4,"week":"2025-W45"},{"count":5,"week":"2026-W32"},{"count":5,"week":"2026-W33"},{"count":1,"week":"2026-W34"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT04513925:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04513925:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04513925:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04513925:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04513925:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:42562209","quote_policy":"short_quote_link_out"},{"id":"openfda:8baba4ea-2855-42fa-9bd9-5a7548d4cec3:20260831","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3msxgckyecc26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3m4sfb64z4n2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ed55dgyglbcqmn5a5aayfrro-3m2r4a2slus26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rrbyloms73nnvhdn43h6esm2-3lmxg346yec2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3m3evwf5jos2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3msprxp4rft2l","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384832912187244544","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7491448479727165440","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7491759658483879936","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:303c76","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:51fea0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b44ff6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1480365169960181766:c327c043-12f6-4687-9b98-76eb0e208723","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1489143995854987266:b04c2cb2-eb09-4297-aec7-37f5ea47f6af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1497238819082547200:ee349321-0fcf-4728-87b6-6bf6153392cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1509071242355163137:52811fd9-25e1-40a5-a10d-c74061d99408","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1519989592946089984:6ec5e68d-8c65-4d8c-9d34-bb36b49cea44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1524432562730549250:0941e2d1-1100-4425-8ac2-454cde1b9d5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1599030819716141056:dd954edf-780f-49a2-b517-698c26f418c0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1641802442663948295:77a6c57b-9c7b-477d-bffe-005050050606","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1641826112127811587:dd5e0366-a10b-4c31-95ab-e8a8980bc3ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1668079356915363840:508bb4c1-b9fa-4027-a31b-0824ee27d1a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716064358839509376:f7af6dd2-5a23-44ca-a60b-6666b193918a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1724412443244527950:37b794ba-6235-439c-9a40-051fbe81d528","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1747030928528941319:b10688ba-0d41-4463-8b79-89a12e8b1151","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1808853228148150663:2b1bc307-3d3a-4b1f-91da-116727075bf2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1830057075038122484:6f3ddff3-1568-47aa-93e1-78aca3b1a08c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855219386396635552:9d9b653c-6aea-4db3-b532-b0d4e7fc7a62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856284861792760281:fc6c4acb-73b2-4c9e-b556-315b385b23fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1858513033158435326:00033fb0-7441-4097-b854-2fe73cfc2c6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1858515016841941437:5dccdc39-50f4-410c-b564-2fdda5f0b5dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970816373917209051:b542fedf-ba2a-4f5a-9179-acb5ec678549","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971195959859347901:e394e90b-4cc9-48d7-85a8-18039a123d3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971196033159123110:31c6a3ad-cdf6-4435-b86e-139399849264","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972844281623933411:72ad61e0-ddb6-4aa8-b368-e5ce9b38ddde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973689496626405807:6fbc0a27-f5ac-4316-83c6-262cab52abbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974173879594537295:daa4b91a-2282-4e52-a106-0fae3747f262","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974495447835177411:0e4a96b4-e066-4644-b288-4ff87c21f127","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975199364462108824:c6e36e81-8f18-4910-b44d-605d7a515ef7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1976544696752099789:bdc20715-9662-4818-97da-ee84836ffc12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978125966418313284:309ad0a0-f9a6-4fa3-986a-f5eceb4bc8e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979450328891183247:d366a4c1-834e-48f9-b578-35b8aed2cf5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979450416791261661:afe330ac-d0b7-4fee-8192-cc485d88fcc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979451340855349486:5f25dad2-87e8-4711-9460-058d7fdae15a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979451436145762378:81d6faaa-08e2-4263-bfb3-5a5740c6fa8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979452076850561341:9372e6f1-3149-43a1-a1ab-347773c3120c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979452226562146522:c528194f-03db-42c7-9476-809eff648729","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979452375011332528:3702417a-f8a3-4fbd-9ac8-3d4855ec2ed8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979453689749205278:b0c602da-6b8d-4880-a4c1-95d0b3955211","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979454294655906084:34f5effa-1056-4529-bca3-ff651640f23b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979460685752078507:08fe928a-a64a-431b-895c-8f27aed40993","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979887755015475303:e96e6f57-b827-4d44-8882-a5f1e30d39df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979985899296354463:123eba86-9121-4bf4-829e-6f95f75bf65a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981084097826152502:d3c8b14c-1323-4ecd-b5b7-8c1f31603e3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982165793124364580:0a0f6f29-9a57-4c97-8146-88550f1c6ca1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1984364755323126041:77c3a15f-ed45-49d9-95ac-0719aea70b10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985664617196953921:70bbc5db-c268-4f30-82b0-917ee227da5d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992138797056921649:2f9f20ba-9bf8-4f08-b5c4-91eb80601176","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2068347329044717786:5c787737-730b-4f20-806e-131b0f74ddfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075734367213887778:01d6b561-5fce-4a05-b7bf-688f9de1cafc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2076069757246153190:34367ebb-e6d6-4758-8247-6ca7f5292e6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085554219642503427:6202edc3-e49a-4068-bf4e-b30891bd1f61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085642885567795691:3c4da632-d403-4e52-b692-3c0a47be3b26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085658913454645475:8703e695-1894-4633-89d8-34697dd619e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085675459434422604:b23126cc-209b-496e-a8d5-8485e7f1ff7a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085980653179502819:bd0b6d55-a807-40ce-8517-4042cd1edfb9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086116673153888759:c60fd6e1-1c7e-48a1-97a5-3c57b195cb83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086352599632998535:b3317f26-2d99-4fb7-b6d7-008dbfb68de3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086575716704162103:7401fd38-3cd5-4e9f-8872-db6a892c497b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086754440216752595:43ef99c0-6e4b-4902-8644-7781f2e99210","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087847008610455553:c820ef7f-93f4-4810-b27d-83af9b0f169c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088203990970278282:d08e23e7-8407-4665-bbed-166b759353ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088261589086687431:226c113d-880e-4f15-a30e-a58df8c909b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088520551643934908:14d2da8d-bf75-47a0-8874-f95ed3f728e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088585460599713807:52e3b733-d790-4d8f-a710-d92d35b933a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089032984251015296:122c2f39-a577-4a71-a9e9-0a7ac393f9be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091531828398039337:3653ccf0-6773-4bfa-8854-519d5e93d68c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098261429698908654:e651b507-aafd-4e9e-90b7-ce53daef7a41","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vCF7UT-9Oww","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":3,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":66,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":79},"count":79,"evidence_window":{"end":"2026-09-11","start":"2022-01-10"},"retrieval_snapshot":"2026-10-31T10:05:21.431483Z","timeline":[{"count":1,"week":"2022-W02"},{"count":1,"week":"2022-W03"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2022-W08"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2022-W15"},{"count":2,"week":"2022-W17"},{"count":1,"week":"2022-W18"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W48"},{"count":2,"week":"2023-W13"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W24"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W43"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2024-W03"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W35"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":2,"week":"2024-W47"},{"count":1,"week":"2025-W16"},{"count":3,"week":"2025-W39"},{"count":4,"week":"2025-W40"},{"count":3,"week":"2025-W41"},{"count":17,"week":"2025-W42"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":4,"week":"2025-W45"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W25"},{"count":2,"week":"2026-W28"},{"count":10,"week":"2026-W32"},{"count":9,"week":"2026-W33"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W37"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"reason":"Unmapped registry intervention: tiragolumab","status":"unmapped"},{"brand_names":["Imfinzi"],"label":"durvalumab","slug":"durvalumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SKYSCRAPER-03","aliases":["SKYSCRAPER-03","A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation"],"brief_title":"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"display_condition":"locally advanced, unresectable stage III NSCLC","display_interventions":[["tiragolumab","atezolizumab"]],"enrollment":{"count":829,"type":"ACTUAL"},"interventions":[{"name":"Atezolizumab","synonyms":["Tecentriq; RO5541267"],"type":"DRUG"},{"name":"Tiragolumab","synonyms":["MTIG7192A; RO7092284"],"type":"DRUG"},{"name":"Durvalumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04513925","official_title":"A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2025-05-27","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate median PFS.","measure":"Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)","timeFrame":"From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)"},{"description":"PFS was defined as the time from randomization to the first occurrence of PD, as determined by an IRF according to RECIST v1.1, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median PFS.","measure":"PFS, as Assessed by an IRF in FAS","timeFrame":"From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)"}],"registered_date":{"date":"2020-08-14","type":"ACTUAL"},"registry_last_updated":"2026-06-03","registry_url":"https://clinicaltrials.gov/study/NCT04513925","short_name":"SKYSCRAPER-03","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2020-08-24","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"GO41854","type":"sponsor_study_id"},{"id":"2019-004773-29","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}